Mineralys Therapeutics Files Q2 2024 10-Q
Ticker: MLYS · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 1933414
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Mineralys Therapeutics filed its Q2 10-Q. Financials and operations detailed.
AI Summary
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with a detailed look at Mineralys Therapeutics' financial health and operational progress during the second quarter of 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Mineralys Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240813 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 13, 2024.
What is Mineralys Therapeutics, Inc.'s primary industry?
Mineralys Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Mineralys Therapeutics, Inc. located?
Mineralys Therapeutics, Inc. is located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087.
What is the fiscal year end for Mineralys Therapeutics, Inc.?
The fiscal year end for Mineralys Therapeutics, Inc. is December 31.
Filing Stats: 4,598 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2024-08-13 16:10:47
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq S
Filing Documents
- mlys-20240630.htm (10-Q) — 676KB
- mlys2q2410qex311.htm (EX-31.1) — 10KB
- mlys2q2410qex312.htm (EX-31.2) — 10KB
- mlys2q2410qex321.htm (EX-32.1) — 5KB
- mlys2q2410qex322.htm (EX-32.2) — 5KB
- 0001933414-24-000039.txt ( ) — 3746KB
- mlys-20240630.xsd (EX-101.SCH) — 29KB
- mlys-20240630_cal.xml (EX-101.CAL) — 34KB
- mlys-20240630_def.xml (EX-101.DEF) — 114KB
- mlys-20240630_lab.xml (EX-101.LAB) — 392KB
- mlys-20240630_pre.xml (EX-101.PRE) — 269KB
- mlys-20240630_htm.xml (XML) — 339KB
- Financial Information
Part I - Financial Information 1
Financial Statements
Item 1. Financial Statements 1
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 27
Controls and Procedures
Item 4. Controls and Procedures 28
- Other Information
Part II - Other Information 29
Legal Proceedings
Item 1. Legal Proceedings 29
Risk Factors
Item 1A. Risk Factors 29
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 29
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 29
Other Information
Item 5. Other Information 29
Exhibits
Item 6. Exhibits 29 i Table of Contents
- Financial Information
Part I - Financial Information
Financial Statements
Item 1. Financial Statements Mineralys Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) June 30, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 67,856 $ 49,304 Investments 243,259 187,263 Prepaid and other current assets 6,886 12,536 Total current assets 318,001 249,103 Investments, noncurrent — 2,482 Property and equipment, net 42 — Other assets 449 51 Total assets $ 318,492 $ 251,636 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,707 $ 601 Accrued liabilities 26,690 9,881 Total current liabilities 28,397 10,482 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 49,710,598 and 41,133,916 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 5 4 Additional paid-in capital 487,320 365,858 Accumulated deficit ( 197,230 ) ( 124,708 ) Total stockholders' equity 290,095 241,154 Total liabilities and stockholders' equity $ 318,492 $ 251,636 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 39,273 $ 11,884 $ 70,027 $ 24,177 General and administrative 5,895 3,851 10,503 6,496 Total operating expenses 45,168 15,735 80,530 30,673 Loss from operations ( 45,168 ) ( 15,735 ) ( 80,530 ) ( 30,673 ) Interest income, net 4,152 3,593 8,005 5,922 Other income 2 1 3 2 Total other income, net 4,154 3,594 8,008 5,924 Net loss $ ( 41,014 ) $ ( 12,141 ) $ ( 72,522 ) $ ( 24,749 ) Net loss per share attributable to common stockholders, basic and diluted $ ( 0.83 ) $ ( 0.31 ) $